The conversation discusses using RU58841, Minoxidil, and finasteride for hair loss treatment. It focuses on homebrewing RU58841 while using other treatments.
The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The conversation discusses a hair loss protocol and compares it to using finasteride and minoxidil. It suggests that while the protocol includes some good advice, it may not surpass the effectiveness of established treatments like finasteride and minoxidil.
Use tretinoin three times a week, dermaroll once a week, and apply minoxidil daily, but avoid using all three on the same day. Tretinoin is preferred over hydrocortisone and should not be used immediately after dermarolling.
The conversation is about choosing between RU58841 and topical spironolactone for hair loss treatment. The user is currently using a topical solution with minoxidil, alfatradiol, and progesterone, and is concerned about side effects and effectiveness of both RU58841 and spironolactone.
User experienced hair loss after surgery and was diagnosed with TE. The doctor recommended PRP therapy, Finasteride, Anatrix pro Hair Serum, a multivitamin, and a lotion and shampoo containing Zinc Pyrithione.
A 17-year-old is looking for alternatives to finasteride for DHT control to preserve hair, considering ketoconazole shampoo for its potential to inhibit 5AR and also thinking about using caffeine-containing shampoos like alpecin or watermans.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
The user received trichotest results indicating finasteride is ineffective for them, and they plan to use dutasteride mesotherapy and add cetirizine to minoxidil. They seek advice on incorporating dutasteride into their regimen.
The user noticed potential hair growth after 13 days of using RU58841, alongside a regimen of oral minoxidil, finasteride, and topical minoxidil. Others think it's too soon to see results, and some are surprised by the high dosage of oral minoxidil.
Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.
The conversation discusses using Tretinoin for treating androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
A 22-year-old male shared his one-year progress using dutasteride, minoxidil, and ketoconazole shampoo for hair regrowth, showing significant improvement. Users discussed the effectiveness of these treatments, with some confusion about ketamine, and shared their own experiences and questions about dosages and side effects.
The conversation is about coping with hair loss and using treatments like finasteride, minoxidil, derma-rolling, RU58841, and hair transplants or systems. The main message is to do your best with available treatments and not let hair loss prevent you from enjoying life.
The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.
The conversation discusses hair regrowth after 7 months of treatment, with the recent addition of tretinoin 0.05%. The treatment routine remained the same as before, except for this new addition.
The user experienced noticeable hair regrowth using topical minoxidil and a dermaroller within a month. They are advised to consider DHT inhibition for lasting results.
RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.
OP mixed RU58841 with minoxidil and initially saw crystals, but realized they were bubbles. They asked for advice on application frequency for a 5% solution.
Using a blunt tip syringe is an effective method for applying liquid topicals like minoxidil and RU58841, especially for those with thick or long hair experiencing diffuse thinning. The user found significant hair regrowth and increased density after using these topicals for less than three months.
Microneedling, comparing dermarollers and dermastamps as treatments for hair loss, and the effectiveness of each. Dermastamps are considered cheaper than dermapens, but users have varying opinions on which method is more effective with less pain.
Rob English's scalp massages are discussed as a method to reduce DHT and stop hair loss, but many users criticize it as ineffective compared to treatments like finasteride, dutasteride, and minoxidil. Some users argue that alternative treatments like scalp massages and microneedling can work for some, but the community largely favors the "big three" medications.
People shared mixed experiences with RU58841 for hair loss; one person saw no improvement, another had significant gains and uses it with finasteride, while a third had an allergic reaction to the premixed solution. Some mix RU58841 powder into minoxidil themselves.
Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.